Designing Cell-Permeable Peptide Therapeutics That Enter the Cell by Endocytosis

ACS Symp Ser Am Chem Soc. 2022:1417:179-197. doi: 10.1021/bk-2022-1417.ch007. Epub 2022 Aug 4.

Abstract

Intracellular protein-protein interactions (PPIs) represent a large class of exciting as well as challenging drug targets for traditional drug modalities (i.e., small molecules and biologics). Peptides (especially cyclic peptides) have proven highly effective as PPI inhibitors in vitro but are generally impermeable to the cell membrane. The recent discovery of a family of highly active cyclic cell-penetrating peptides (CPPs) has enabled the delivery of peptides into the cytosol of mammalian cells at therapeutically relevant levels. This chapter describes the various strategies that have been developed to conjugate or integrate different types of peptidyl cargoes (e.g., linear, cyclic, and stapled peptides) with cyclic CPPs to generate cell-permeable, metabolically stable, and biologically active macrocyclic peptides against intracellular targets including PPIs.

Keywords: Cyclic peptides; cyclic cell-penetrating peptides; protein-protein interaction; reversible cyclization.